MAR001

Phase 2Small molecule

MMarea Therapeutics

MAR001 is one of 24 small molecule programs targeting Hypertriglyceridemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypertriglyceridemiaRecruiting

CholesterolRecruiting

HypertriglyceridemiaPhase 2

Recruiting

CholesterolPhase 2

Recruiting

Competition

Competitive Landscape

17 competitors in Hypertriglyceridemia

#DrugCompanyPhaseTrials

Crestor

Cipro

Selzentry

Lopid

Topamax

Zocor

Tryngolza (autoinjector)

Ionis Pharmaceuticals

Phase 3

3 8

Redemplo

Arrowhead Pharmaceuticals

Phase 3

3 9

Avandia

Jazz Pharmaceuticals

Preclinical

1 10

Repatha

Amgen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Cholesterol

NCT07199309

Q2 2028

Phase 2Recruiting

Hypertriglyceridemia

NCT07028749

Clinical

Trials by Indication[1]

Cholesterol1 trial

A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol

Recruiting·MMarea Therapeutics·Phase 2·NCT07199309·30 enrolled

Function1 trial

Study of MAR001 in Adults With Metabolic Dysfunction

Completed·MMarea Therapeutics·Phase 1/2·NCT05896254·55 enrolled

Hypertriglyceridemia1 trial

Phase 2b Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of MAR001 in Patients With Elevated Triglycerides and Remnant Cholesterol (TYDAL-TIMI 78)

Recruiting·MMarea Therapeutics·Phase 2·NCT07028749·316 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for MAR001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MAR001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MAR001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Marea Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMarea Therapeutics

MAR001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2028

Trials by Indication[1]

Cholesterol1 trial

Function1 trial

Hypertriglyceridemia1 trial

References

Drug Info

Quick Facts

Related News